NEW YORK, April 11 (GenomeWeb News) - Myriad Genetics and Abbott said today that they have entered into a "broad drug-discovery collaboration" to identify unspecified therapeutic targets of interest.
The five-year research agreement calls for Myriad to use its RNA expression profiling and "other technologies" to identify human genes and regulatory networks associated with a variety of diseases, the companies said.
Abbott will then advance these genes through to its chemical genomics platform to identify targets and leads for drug discovery.
Each company will have exclusive rights to the therapeutic targets and drug lead compounds, with Myriad receiving rights to approximately 40 percent of the targets, and Abbott receiving rights to approximately 60 percent, the companies said.
Myriad and Abbott officials could not be reached for comment.